Rapid Hybridoma
Hybridoma antibody technology produces monoclonal antibodies but faces challenges like instability and the need for liquid nitrogen preservation. Hybridoma sequencing enables recombinant expression, ensuring stability and preventing biological contamination.
InnoTrace offers high-accuracy hybridoma sequencing and recombinant antibody expression, achieving 200-500 mg/L yields in 2 weeks with the proprietary pATX3.0 vector.
At InnoTrace, we pride ourselves on over 10 years of expertise in delivering custom hybridoma monoclonal antibody services. Our process is designed to meet the highest standards of quality and efficiency, ensuring your research and therapeutic projects are supported by the best monoclonal antibodies available.
Secure your investments with stable cell line development services achieving yields exceeding 7g/L.
Access royalty-free cell lines such as CHO-1, CHO-S, CHO-DG44, HEK293, or your preferred choice.
Access royalty-free cell lines such as CHO-1, CHO-S, CHO-DG44, HEK293, or your preferred choice.
Reduce production risks with extensive early testing of antibody candidates.
Fast cell line and protocol transfer to CMO partners for cGMP bioproduction.
500+ monoclonal antibodies developed, 100+ stable cell lines generated, 28+ years of expertise.
Rapid Hybridoma Case Studies
Figure 1: Schematic of Antibody Coding Gene Structure (including 5’ and 3’ untranslated regions)
Figure 2: PCR Amplification of Heavy and Light Chain Variable Regions
Figure 3: Colony PCR Validation Gel
M: DL10000 DNA Marker; 1% Agarose Gel
Figure 4: Antibody Heavy and Light Chain Sequence Analysis
Figure 5: Antibody Heavy and Light Chain Sequencing Peak Map
More Featured Antibody Services
